FIM
PLRX icon

Fernwood Investment Management’s Pliant Therapeutics PLRX Stock Holding History

Fernwood Investment Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$5.6M Sell
425,424
-87,712
-17% -$1.2M 1.95% 12
2024
Q3 		$5.75M Buy
513,136
+16,850
+3% +$211K 1.87% 13
2024
Q2 		$5.34M Buy
496,286
+47,901
+11% +$617K 1.65% 14
2024
Q1 		$6.68M Buy
448,385
+25,208
+6% +$416K 1.95% 13
2023
Q4 		$7.66M Buy
423,177
+43,475
+11% +$661K 2.53% 7
2023
Q3 		$6.58M Sell
379,702
-1,025
-0.3% -$17.8K 2.37% 6
2023
Q2 		$6.9M Buy
380,727
+67,479
+22% +$1.6M 2.45% 6
2023
Q1 		$8.33M Buy
313,248
+8,675
+3% +$247K 3.2% 4
2022
Q4 		$5.89M Buy
304,573
+81,816
+37% +$1.71M 2.44% 4
2022
Q3 		$4.65M Buy
222,757
+10,547
+5% +$202K 1.96% 9
2022
Q2 		$1.7M Buy
212,210
+26,100
+14% +$167K 0.73% 37
2022
Q1 		$1.76M Buy
186,110
+11,850
+7% +$121K 0.62% 47
2021
Q4 		$2.35M Buy
174,260
+7,813
+5% +$124K 0.77% 31
2021
Q3 		$2.81M Buy
166,447
+15,336
+10% +$325K 0.97% 29
2021
Q2 		$4.41M Buy
+151,111
New +$4.7M 1.46% 15

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fernwood Investment Management's PLRX Position: Q4 2024 in Review

Fernwood Investment Management reduced its Pliant Therapeutics (PLRX) stake by 17% in Q4 2024, selling an estimated $1.2M and leaving 425,424 shares worth $5.6M. The position accounts for 1.95% of the portfolio, ranked #12.

Fernwood Investment Management first reported a position in PLRX in Q2 2021 and has held it in 15 quarters since. The position peaked at $8.33M in Q1 2023. 160 funds tracked by Wall St. Rank hold PLRX as of Q4 2024.

  • Fernwood Investment Management held 425,424 shares of Pliant Therapeutics worth $5.6M as of Q4 2024.
  • Fernwood Investment Management sold 87,712 Pliant Therapeutics shares in Q4 2024, an estimated $1.2M.
  • Pliant Therapeutics made up 1.95% of Fernwood Investment Management's portfolio in Q4 2024, its #12 holding.
  • Fernwood Investment Management first reported a position in Pliant Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • Fernwood Investment Management's Pliant Therapeutics position peaked at $8.33M in Q1 2023.
  • 160 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2024.

Based on Fernwood Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.